Full Press Release Details
Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
ANTONIO, TX (Oct. 18, 2024) - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused
on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase
agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a
registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants (the "Warrants")
to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share. The Warrants are initially exercisable
on the date that the Company's stockholders approve the exercise of the Warrants and the issuance of the shares upon exercise thereof
and will expire five years from the date of such approval.
closing of the offering is expected to occur on or about Oct. 21, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds from the offering are expected to be approximately $2,662,782 excluding any proceeds that may be received upon the
exercise of the Warrants and before deducting placement agent fees and other offering expenses payable by the Company.
Capital is acting as sole placement agent for the offering.
Shares of common stock will be issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3
(File No: 333-275608) previously filed with the U.S. Securities and Exchange Commission (SEC), under the Securities Act of 1933, as amended,
and declared effective by the SEC on Nov. 27, 2023. A prospectus supplement describing the terms of the proposed registered direct offering
will be filed with the SEC and available on the SEC's website located at http://www.sec.gov. Electronic copies of the prospectus
supplement may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1
(646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311,
private placement of the Warrants will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities
Act and/or Regulation D thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold
in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements
of the Securities Act and such applicable state securities laws.
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that
indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung
incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results
demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high
risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve
outcomes and increase patient survival. For more information, visit www.cypathlung.com.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW)
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and
broad-spectrum cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown
high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a
Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more
press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company's
offering of securities and the expected closing of the offering. Forward-looking statements can be identified by words such as "believes,"
"expects," "estimates," "intends," "may," "plans," "will" and
similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist
at the time such statements are made and predictions as to future facts and conditions and include that the closing of the offering is
expected to occur on October 21, 2024. Readers of this press release are cautioned not to place undue reliance on any forward-looking
statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are outside of the Company's control. Many factors could cause actual
future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and
uncertainties included under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q filed by the Company and other reports filed with the SEC from
time to time. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in
this press release, except as may be required by applicable securities laws.
(733-2447) or 407-491-4498